Antioxidant Status, Inflammation

4 week intervention with 700g (raw weight) of pork meat (3x pork burgers (125g raw weight each) + pork mince (325 g raw weight) per week.

Pork meat from pigs feed with a standard feed.

4 week intervention with 700g (raw weight) of pork meat (3x pork burgers (125g raw weight each) + pork mince (325 g raw weight) per week from pigs fed animal feed supplemented (5.37 kg/tonne of feed) with spray-dried laminarin and fucoidan (seaweed).

Human Intervention Studies Unit, Ulster University

Effect of Consuming Pork From Seaweed Extract Fed Animals on Antioxidant Status

Effect of Consuming Pork From Animals Supplemented With Laminarin and Fucoidan Derived From the Brown Seaweed Laminaria Digitata on the Antioxidant Status of Human Participants.

Lymphocyte DNA damage prior to and following an oxidative challenge with hydrogen peroxide.

University of Ulster

University College Dublin

University College Cork

Inflammatory Bowel Disease patients followed in Saint-Etienne Hospital since 3 years or more. Blood specimen 3 years after a first blood specimen

blood specimen in IBD cohort of 195 patients followed in Saint-Etienne Hospital

Crohn's Disease

Ulcerative Colitis

Inflammatory Bowel Disease

blood specimen

CHU Saint-Etienne

Study of Anti-glycan Antibodies Stability in Saint-Etienne IBD Cohort

Study of Anti-glycan Antibodies Stability in Saint-Etienne IBD Cohort - A Monocentric Study

Immunological status is defined by anti-glycan antibodies (ACCA, ALCA, AMCA, anti-chitin and anti-laminarin), ASCA and ANCA.
Antibody will be positive if level is found higher than the threshold defined by the laboratory (technical threshold).
An antibody will be defined as stable if its status remains positive during 3 years(above the detection limit given by the reference laboratory) or negative during 3 years (below the detection limit given by the reference laboratory). Conversely, the lack of stability during 3 years will be defined as the transition from a positive to a negative status or inversely.

Comparison of clinical remission between patients with a change in their immunological status and patients with stable status.
A patient is in clinical remission if:
Crohn's disease activity index (CDAI) score is lower than 150 for Crohn's disease
Lichtiger score is < 4 for Ulcerative Colitis

Comparison of anti-TNF (Tumor Necrosis Factor) therapeutic response between patients with a change in their immunological status and patients with stable status.
A patient is considered as anti-TNF responder if there is a clinical remission without therapeutic change in the medical history of the patient

Comparison of mucosal healing between patients with a change in their immunological status and patients with stable status.
A patient will be considered in mucosal healing if:
C-reactive Protein (CRP) < 5mg/L and fecal calprotectin <250 µg/g
Fecal calprotectin <150 µg/g in Ulcerative colitis

Comparison of intestinal permeability between patients with a change in their immunological status and patients with stable status.
4. Normalization of intestinal permeability will be defined if lipopolysaccharide (LPS) or anti-LPS Antibodies (IgG) level measured by LAL or ELISA is significantly reduced between the two samples. As there is no pre-defined threshold for LPS and anti-LPS Antibodies level in normalization of intestinal permeability, we will calculate a delta (level before - level at 3 years) for each patient and each parameter. We will analyze the average delta with the stability or not of immunological status.

Comparison of number of surgical resection between patients with a change in their immunological status and patients with stable status.
5. Surgical resection may be a colonic or small bowel resection surgery for CD patients or colectomy for UC patients.

Centre Hospitalier Universitaire de Saint Etienne

5 g/d placebo (maltodextrin)in 10 500-mg capsules for 1 month

Seaweed (Undaria pinnatifida) given orally in ten 500-mg capsules for 1 month

5 g/d placebo in 10 500-mg capsules for one month

Seaweed Associated Changes in Healthy Subjects

Ten 500-mg capsules to be taken orally each day for 1 month

Seaweed

Placebo

Placebo2

University of South Carolina Cancer Research Center

Dietary Seaweed and Early Breast Cancer: A Randomized Trial

SELDI-TOF-MS was used to measure urinary and serum protein changes

Urinary iodine concentration changes were used to indicate adherence to taking the seaweed supplement.

laminarin/inflammation

Effect of Consuming Pork From Seaweed Extract Fed Animals on Antioxidant Status

Study of Anti-glycan Antibodies Stability in Saint-Etienne IBD Cohort

Dietary Seaweed and Early Breast Cancer: A Randomized Trial

科学支持的最完整的草药数据库